Genmab | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
Almirall EUR -50222000 162.22M 2024-06
Amarin USD 36.9M 1.64M 2024-09
Amgen USD 1.88B 253M 2024-12
argenx SE USD 285.94M 8.24M 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Bayer EUR 4.34B 610M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Demant DKK 5.63B 2.77B 2024-12
Exelixis USD 134.33M 22.53M 2025-01
Fresenius Medical Care EUR 840M 84M 2024-12
Galapagos EUR 41.25M 11.98M 2024-12
Genmab DKK 1.25B 384M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
GN Store Nord DKK 1.62B 230M 2024-12
GRIFOLS EUR 269.48M 49.95M 2024-12
Hikma Pharmaceutical USD 280M 4M 2024-06
Insmed USD 142.51M 23.58M 2024-12
Merck EUR 1.05B 361M 2024-12
Novartis USD 3.5B 368M 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 2.68B 26M 2024-09
UCB EUR 533M 434M 2024-06



Genmab Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Apr 2025.